Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (DE:LGDN)
FRANKFURT:LGDN
Ligand Pharma (LGDN) Stock Price & Analysis
1 Followers
LGDN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€47.00 - €82.00
Previous Close€65
Volume0.00
Average Volume (3M)4.00
Market Cap
€1.16B
Enterprise Value€983.32M
Total Cash (Recent Filing)$190.50M
Total Debt (Recent Filing)$6.33M
Price to Earnings (P/E)N/A
Beta0.87
Next Earnings
May 07, 2024EPS Estimate
€0.78Last Dividend Ex-Date
Nov 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,705,287
10 Day Avg. Volume0
30 Day Avg. Volume4
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.22
Price to Sales (P/S)5.82
Price to Cash Flow (P/CF)39.00
P/FCF Ratio38.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit6.86
Enterprise Value/Ebitda7.52
Forecast
1Y Price Target
€108.64Price Target Upside67.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Ligand Pharma News
PremiumCompany Announcements
Ligand Pharmaceuticals Inc’s New Competition Risk – A Cause for Worry?
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
6.15% Other Institutional Investors
93.85% Public Companies and
Individual Investors
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was €47.00 and its highest was €82.00 in the past 12 months.
What is Ligand Pharma’s market cap?
Currently, no data Available
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is May 07, 2024 which is in 7 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Feb 27, 2024. The company reported €1.289 earnings per share for the quarter, beating the consensus estimate of €0.617 by €0.671.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of €28.03 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is €0.78.
How many shares outstanding does Ligand Pharma have?
Currently, no data Available
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of €1.289 in its last earnings report, beating expectations of €0.617. Following the earnings report the stock price went down -1.449%.
Which hedge fund is a major shareholder of Ligand Pharma?
Among the largest hedge funds holding Ligand Pharma’s share is Fisher Asset Management LLC. It holds Ligand Pharma’s shares valued at 4M.
---
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€108.64 (67.14% Upside)
€108.64 (67.14% Upside)
Blogger Sentiment
Bullish
DE:LGDN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.11%
12-Months-Change
Fundamentals
Return on Equity
8.29%
Trailing 12-Months
Asset Growth
3.22%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
---
LGDN Earnings Call
Q4 2024
0:00 / 0:00
---
LGDN Stock 12 Months Forecast
Average Price Target
€108.64
▲(67.14% Upside)
Technical Analysis
Best Analysts Covering LGDN
1 Year
1 Year Success Rate
17/23 ratings generated profit
1 Year Average Return
+33.77%
reiterated a buy rating 12 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +33.77% per trade.
---